Wilmington, Del.– Incyte has appointed veteran pharmaceutical executive Bill Meury as its new President and Chief Executive Officer, marking a leadership transition as current CEO Hervé Hoppenot steps down after more than a decade at the helm.
Meury, who previously led Anthos Therapeutics and Karuna Therapeutics, brings extensive experience from his two decades at Allergan, where he oversaw a $16 billion global business as Chief Commercial Officer. He assumes the top role at Incyte immediately and joins the company’s board of directors.
Hoppenot will remain on the board through the end of the year and serve as an advisor during the transition.
The company also announced that Julian Baker, co-founder of biotech investment firm Baker Bros. Advisors, has been elected Chairman of the Board.
During Hoppenot’s 11-year tenure, Incyte evolved from a single-product U.S.-based company into a global pharmaceutical player. The company launched multiple new drugs, expanded into Europe, Japan, and Canada, and grew annual revenue from $355 million in 2013 to over $4 billion today.
Board Chairman Julian Baker credited Hoppenot with fostering a culture of innovation and steady growth, while expressing confidence in Meury’s ability to accelerate Incyte’s pipeline and commercial efforts, particularly in oncology and immunology.
Meury said he plans to build on Incyte’s research and development strengths to drive sustainable growth and deliver new treatments to patients. “It’s an honor to join Incyte at this pivotal time,” he said.
The leadership change follows a succession planning process initiated by Hoppenot in 2023.
